Efficacy and safety of low-molecular-weight heparin after knee arthroscopy: A meta-analysis

Hai-Feng Huang¹,², Jia-Liang Tian², Xian-Teng Yang¹,², Li Sun², Ru-Yin Hu², Zhi-Hui Yan², Shan-Shan Li³, Quan Xie⁴*, Xiao-Bin Tian²*

¹ Medical College, Guizhou University, Guiyang, Guizhou, China, ² Department of Orthopaedics, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China, ³ Department of Anesthesiology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China, ⁴ College of Big Data and Information Engineering, Guizhou University, Guiyang, Guizhou, China

* txb6@vip.163.com (XBT); qxie@gzu.edu.cn (QX)

Abstract

Background

Venous thromboembolism (VTE) is considered a potentially serious complication of knee arthroscopy and leads to conditions such as deep venous thrombosis (DVT) and pulmonary embolism (PE). Low-molecular-weight heparin (LMWH) is widely employed in knee arthroscopy to reduce perioperative thromboembolic complications. However, the efficacy and safety of LMWH in knee arthroscopy remains unclear.

Methods

Seven randomized controlled clinical trials on LMWH in knee arthroscopy were identified and included in this meta-analysis. The main outcomes of the effectiveness (prevention of DVT and PE) and complications (death, major bleeding, and minor bleeding) of LMWH in knee arthroscopic surgery were assessed using Review Manager 5.3 software.

Results

The meta-analysis indicated that LMWH prophylaxis comprised 79% of asymptomatic DVT. No association was found in symptomatic VTE (RR: 0.90; 95% confidence interval [CI]: 0.39–2.08; P = 0.80), symptomatic DVT (RR: 0.79; 95% CI: 0.28–2.23; P = 0.66), symptomatic PE (RR: 1.36; 95% CI: 0.37–4.97; P = 0.64) and major bleeding (RR: 0.70; 95% CI: 0.12–3.95; P = 0.68) risk during LMWH prophylaxis were identified. Death was not reported in these studies. Moreover, there was a lower incidence of minor bleeding (RR: 0.64; 95% CI: 0.49 to 0.83; P = 0.001) in the control group than in the LMWH group.

Conclusion

Compared with the control group, the group treated with LMWH after knee arthroscopy was no association in reducing the symptomatic VTE rate, symptomatic DVT rate or symptomatic PE rate. The symptomatic VTE rate was 0.5% (11/2,166) in the LMWH group versus 0.6% (10/1,713) in the control group. Although the limitations of this meta-analysis cannot
be ignored, the results of our study show that LMWH after knee arthroscopy is ineffective. We recommend that LMWH should not be routinely provided for knee arthroscopy.

**Trial registration**
ClinicalTrials.gov NCT03164746

---

**Introduction**

Knee arthroscopy has become one of the most common surgical methods for the knee. Many patients suffering from knee diseases experience satisfactory curative effects using this method. However, severe clinical symptoms, including deep venous thrombosis (DVT) and pulmonary embolism (PE), have occurred during the postoperative period. Venous thromboembolism (VTE) after knee arthroscopy is not an uncommon complication and is an important health problem. Following arthroscopic knee surgery, patients are at an increased risk of complications associated with VTE (i.e., DVT or PE). [1] Complications of VTE include PE, which may be fatal. VTE is a disease that causes a major health burden in different countries and regions. [2] Therefore, effective postoperative prevention of VTE appears to be critical to operative success. Anticoagulants are the main prophylaxis for VTE. Studies have indicated that patients undergoing knee arthroscopy receive effective prophylaxis of VTE using Low-molecular-weight heparin (LMWH). [3–7] Furthermore, a recent meta-analysis indicated that LMWH has the potential to prevent thromboembolic events in non-major orthopaedic settings compared with no treatment. [8] However, a recent randomized controlled trial (RCT) showed that the use of LMWH after knee arthroscopic surgery is not effective for preventing symptomatic VTE. [9] Thus, the efficacy of LMWH in knee arthroscopy remains controversial.

LMWHs, such as tinzaparin, dalteparin and enoxaparin, have high potentials for patient administration and bioavailability. [10–11] VTE prophylaxis with LMWH is indicated for patients after arthroscopic surgery, and some studies indicate that patients received beneficial effects; however, disadvantages also exist with LMWH. The potential risk of bleeding following the use of LMWH is unavoidable. Moreover, no meta-analysis has investigated the safety of LMWH in patients after knee arthroscopy. The debate regarding whether the use of LMWH has a preventive effect after knee arthroscopy is ongoing. The purpose of this meta-analysis is to assess the efficacy and safety of LMWH in arthroscopic surgery of the knee.

**Methods**

**Search strategy**

All eligible studies were obtained from PubMed, EMBASE and the Cochrane Library. The following search terms, including keyword or entry terms, were used without limitations through September 2017: ‘arthroscopy OR arthroscopic OR arthroscopically’ AND ‘Heparin, Low-Molecular-Weight OR Heparin, Low Molecular Weight OR LMWH OR Low-Molecular-Weight Heparin OR Low-Molecular-Weight Heparin’. We manually screened the relevant review articles in the reference lists.

**Selection criteria**

The following trials were identified and included in this study: (1) patients treated with knee arthroscopy, (2) patients who received LMWH after knee arthroscopy, (3) outcomes included
efficacy (DVT, PE) and safety (major bleeding, minor bleeding), and (4) studies were random-
ized controlled clinical trials.

Data extraction
For each study, two independent authors, using a standardized data extraction form, extracted
the following data: authors, year of publication, study quality, intervention, population, patient
characteristics, and outcomes. We accepted the authors’ definitions of the results and did not
reclassify the events. The efficacy endpoint was VTE (symptomatic VTE, asymptomatic DVT,
symptomatic DVT and symptomatic PE) in the studies. DVT confirmation was required by
venography or compression ultrasound, including asymptomatic and symptomatic DVT.
Symptomatic PE confirmation was required by pulmonary angiography, ventilation-perfusion
lung scanning or helical computed tomography. The primary safety endpoint was defined as
major bleeding or all-cause death. The secondary safety endpoint was defined as a minor
bleeding event.

Quality assessments
To evaluate the risk of bias of the selected studies, the Cochrane Collaboration tool was used.
For each study, individual team members judged the risk of bias in a given study and deter-
mined it to be “low”, “high”, or “unclear”. Each disagreement was referred to a third team
member.

Statistical analysis
All statistical data were entered into Review Manager version 5.3 software (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration). Random- or fixed-effects models
were used to calculate the summary risk based on the heterogeneity levels. Heterogeneity
between studies was estimated using the $I^2$ statistic. In the heterogeneity levels across studies,
$I^2$ measured the quantitative inconsistency. $I^2$ values from 25% to 50% showed low heterogene-
ity, values from 50% to 75% exhibited moderate heterogeneity, and $I^2$ values $>75%$ showed
high heterogeneity. An $I^2$ value $>0.50$ and a $P$-value for heterogeneity $<0.10$ indicated signifi-
cant heterogeneity.

Results

Literature search and study characteristics
The details of the search strategy are shown in Fig 1. According to the search strategy and
inclusion criteria, 245 articles were identified through the initial search, of which 7 random-
ized controlled trials [3–7,9,12] comprising 3,879 patients (2,166 individuals in the LMWH
group and 1,713 individuals in the control group) were included in our meta-analysis. The
Cochrane Collaboration tool was used to evaluate the quality of the eligible studies (Fig 2).
Table 1 shows the main characteristics of the 7 studies.

Efficacy of LMWH
All seven randomized controlled trials, which included 3,879 patients, reported the efficacy
(symptomatic VTE, symptomatic DVT and symptomatic PE) of LMWH use after knee arthro-
scopic surgery. However, only five randomized controlled trials, which included 2,392
patients, reported the efficacy of asymptomatic DVT. We used the random-effects model to
combine asymptomatic DVT data according to notable heterogeneity ($I^2$ value $= 55\%$). Com-
pared with the control group, after arthroscopic knee surgery, the incidence of asymptomatic
243 records identified through database searches:
- PubMed (n=70)
- Embase (n=154)
- Cochrane Library (n=19)

2 of additional records identified through other sources

62 of records after duplicates removed

183 of records screened

174 of records excluded based on abstract

2 of full-text articles excluded, with reasons:
- Studies did not investigate LMWH prophylaxis: 1
- Studies with no comparative groups: 1

9 of full-text articles assessed for eligibility

7 of studies included in qualitative synthesis (meta-analysis)

Fig 1. Flowchart of the screened, excluded, and analysed publications.

https://doi.org/10.1371/journal.pone.0197868.g001
DVT in the LMWH group was lower (RR: 0.21; 95% CI: 0.07–0.63; P = 0.005, Fig 3). We used the fixed-effects model to combine symptomatic VTE data according to lower significant heterogeneity ($I^2$ value = 0%). Compared with the control group, after arthroscopic knee surgery, the incidence of symptomatic VTE in the LMWH group was not significantly different (RR: 0.90; 95% confidence interval [CI]: 0.39–2.08; P = 0.80, Fig 4). The fixed-effects model was used to combine symptomatic DVT data because heterogeneity was not evident ($I^2$ value = 0%). The symptomatic DVT rate was 0.3% (6/2,166) in the LMWH group versus 0.4% (7/1,713) in the control group. In the overall data, the symptomatic DVT rate in the control group was not significantly different from that in the LMWH group (RR: 0.79; 95% CI: 0.28–2.23; P = 0.66, Fig 5). As a result of the lower heterogeneity of the data ($I^2$ value = 0%), we used the fixed-effects model to combine the symptomatic PE data. The meta-analysis demonstrated that the symptomatic PE
Table 1. Characteristics of the 7 selected clinical studies.

| Study       | Study style | Medicine group | LMWH type, dose and average use time | No. of patients | Sex | Age, year | BMI, kg/m² | Average operation time (min) | Tourniquet used (patients) | Average tourniquet inflation time (min) | Primary outcome event and classification (asymptomatic DVT; diagnosed by compression ultrasound or venography) | Secondary outcome event and classification (symptomatic VTE excluding distal VTE; diagnosed by clinical assessment) |
|-------------|-------------|----------------|--------------------------------------|-----------------|-----|-----------|------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Roth 1995[3] | RCT         | LMWH           | 0.3 ml Fraxiparine; 4 days after surgery | 61              | NA  | NA        | NA         | NA                           | NA                           | NA                              | 0                                                                               | 1                                                                               |
| Wirth 2001[4] | RCT         | LMWH           | Reviparin; 1,750 IU; 7 to 10 days     | 117             | 81/36| 37.6      | The average height was 176 cm, and the body weight was 80.7 kg. | 39                           | 117                            | 42                              | 1                                                                               | 0                                                                               |
| None        | None        | 122            | 38.5                                 |                 |     |           |                         |                              |                                | 29                              | 2                                                                               | 0                                                                               |
| Michot 2002[5] | RCT         | LMWH           | Dalteparin; 2,500 IU if weight <70 kg, 5,000 IU if >70 kg; 30 days | 66              | 40/26| 42.0      | 26.2                   | 42.3                         | 44                            | NA                              | 1                                                                               | 0                                                                               |
| None        | None        | 64             | 46.5                                 |                 |     |           |                         |                              |                                | 40                              | NA                              | 10                                                              | 0                                                                               |
| Canata 2003[12] | RCT        | LMWH           | Enoxaparin; no dose specified; 6 days | 18              | 12/6 | 29.6      | NA                     | NA                           | NA                            | 40                              | NA                              | 0                                                                               | 0                                                                               |
| None        | None        | 18             | 32.5                                 |                 |     |           |                         |                              |                                | NA                              | NA                              | 0                                                                               | 0                                                                               |
| Marlovits 2007[6] | RCT       | LMWH           | Enoxaparin; 40 mg; 20 days           | 72              | 45/27| 41.7% of patients aged >30 years | NA                     | 50% patients (length of operation >2 hours) | NA                            | NA                              | 2                                                                               | 0                                                                               |
| Placebo     |             | 68             | 37/31                                |                 |     |           |                         |                              |                                | 50% patients (length of operation >2 hours) | NA                              | 25                                                              | 3                                                                               |

(Continued)
| Study style | Medicine group | LMWH type, dose and average use time | No. of patients | Sex M/F | Age, year | BMI, kg/m² | Average operation time (min) | Tourniquet used (patients) | Average tourniquet inflation time (min) | Primary outcome event and classification (asymptomatic DVT; diagnosed by compression ultrasound or venography) | Secondary outcome event and classification (symptomatic VTE excluding distal VTE; diagnosed by clinical assessment) |
|---|---|---|---|---|---|---|---|---|---|---|
| RCT | LMWH | Nadroparin; 3800 IU; 7 days or 14 days | 1101 | 679/422 | 42.1 | 25.4 | NA | 1101 | 38 | 15 | 5 |
| Graduated compression stockings | | | 660 | 412/248 | 42.3 | 25.5 | NA | 660 | 36 | 17 | 3 |
| RCT | LMWH | Nadroparin or dalteparin; 2500 IU of dalteparin or 2850 IU of nadroparin were used for patients who weighed 100 kg or less, and a double dose was used for patients who weighed more than 100 kg; 8 days | 731 | 414/317 | 48.1 | 27.1 | 26 | 688 | NA | NA | 5 |
| None | | | 720 | 396/324 | 49.1 | 26.8 | 26 | 673 | NA | NA | 3 |

BMI = body mass index; NA = not available

https://doi.org/10.1371/journal.pone.0197868.t001

Fig 3. LMWH versus control. Asymptomatic deep vein thrombosis during follow-up.

https://doi.org/10.1371/journal.pone.0197868.g003
rate was not significantly affected by LMWH treatment after knee arthroscopy (RR: 1.36; 95% CI: 0.37–4.97; P = 0.64, Fig 6).

Safety of LMWH

The studies included 3,879 patients and reported the safety of LMWH, including the side effects of major bleeding and minor bleeding after knee arthroscopy, in the two groups. The fixed-effects model was used to combine the major bleeding data because of its low heterogeneity ($I^2$ value = 0%). In the combined data, this model showed no significant difference between the LMWH and control groups with respect to major bleeding during the postoperative period (RR: 0.70; 95% CI: 0.12–3.95; P = 0.68, Fig 7). The major bleeding rate was 0.2% (4/2,166) in the LMWH group versus 0.1% (2/1,713) in the control group. Because of its low heterogeneity ($I^2$ value = 0%), we used the fixed-effects model to combine the minor bleeding data. The minor bleeding rate was 6.5% (140/2,166) in the LMWH group versus 4.5% (77/1,713) in the control group. The rate of minor bleeding was significantly lower in the control group than in the LMWH group (RR: 0.64; 95% CI: 0.49–0.83; P = 0.001, Fig 8). It should be noted that in all studies, which included 3,879 patients, there were no deaths reported after knee arthroscopy.
Sensitivity analysis

In the sensitivity analyses, the outcome of asymptomatic DVT was included because of the notable heterogeneity. To analyse the source of heterogeneity, we eliminated articles one by one. The results showed that when the articles written by Camporese et al. or Marlovits et al. were removed, the heterogeneity was significantly reduced ($I^2$ value = 0%; RR: 0.12; 95% CI: 0.04–0.31 or $I^2$ value = 15%; RR: 0.37; 95% CI: 0.16–0.84). Based on this result, we carefully reviewed the original research to determine the factors that caused heterogeneity in these studies. We determined that a methodological inconsistency was the cause of the heterogeneity. In the study by Camporese et al., the patients in the control group did not use LMWH to prevent thrombotic events; instead, compression stockings were used. In the study by Marlovits et al., all surgical patients during hospitalization were administered LMWH to prevent DVT, with no differentiation into groups. When patients were discharged, they were subsequently divided into LMWH and control groups. Thus, the use of LMWH before surgery or compression stockings in the control group may have had an impact on the incidence of asymptomatic DVT.

| Study or Subgroup   | LMWH Events | Control Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---------------------|-------------|----------------|-------|--------|-----------------------------|
| Camporese 2008      | 4           | 6             | 10    | 62.3%  | 1.20 [0.22, 6.53]            |
| Canata 2003         | 0           | 2             | 2     | Not estimable |                            |
| Marlovits 2007      | 0           | 2             | 2     | Not estimable |                            |
| Michot 2002         | 0           | 1             | 1     | 12.6%  | 2.91 [0.12, 70.15]           |
| Roth 1995           | 0           | 1             | 1     | Not estimable |                            |
| Van Adrichem 2017   | 0           | 1             | 1     | 25.1%  | 0.98 [0.06, 15.72]           |
| Wirth 2001          | 0           | 1             | 1     | Not estimable |                            |
| **Total (95% CI)**  | 2166        | 1713          | 3879  | 100.0% | 1.36 [0.37, 4.97]            |

Fig 6. LMWH versus control. Symptomatic pulmonary embolism during follow-up.

https://doi.org/10.1371/journal.pone.0197868.g006

Sensitivity analysis

In the sensitivity analyses, the outcome of asymptomatic DVT was included because of the notable heterogeneity. To analyse the source of heterogeneity, we eliminated articles one by one. The results showed that when the articles written by Camporese et al. or Marlovits et al. were removed, the heterogeneity was significantly reduced ($I^2$ value = 0%; RR: 0.12; 95% CI: 0.04–0.31 or $I^2$ value = 15%; RR: 0.37; 95% CI: 0.16–0.84). Based on this result, we carefully reviewed the original research to determine the factors that caused heterogeneity in these studies. We determined that a methodological inconsistency was the cause of the heterogeneity. In the study by Camporese et al., the patients in the control group did not use LMWH to prevent thrombotic events; instead, compression stockings were used. In the study by Marlovits et al., all surgical patients during hospitalization were administered LMWH to prevent DVT, with no differentiation into groups. When patients were discharged, they were subsequently divided into LMWH and control groups. Thus, the use of LMWH before surgery or compression stockings in the control group may have had an impact on the incidence of asymptomatic DVT.

| Study or Subgroup   | Control Events | LMWH Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---------------------|----------------|-------------|-------|--------|-----------------------------|
| Camporese 2008      | 1              | 3           | 4     | 69.4%  | 0.56 [0.06, 5.33]            |
| Canata 2003         | 0              | 0           | 0     | Not estimable |                            |
| Marlovits 2007      | 0              | 0           | 0     | Not estimable |                            |
| Michot 2002         | 0              | 0           | 0     | Not estimable |                            |
| Roth 1995           | 0              | 0           | 0     | Not estimable |                            |
| Van Adrichem 2017   | 1              | 1           | 2     | 30.6%  | 1.02 [0.06, 16.20]           |
| Wirth 2001          | 0              | 0           | 0     | Not estimable |                            |
| **Total (95% CI)**  | 1713           | 2166        | 3879  | 100.0% | 0.70 [0.12, 3.95]            |

Fig 7. LMWH versus control. Major bleeding during follow-up.

https://doi.org/10.1371/journal.pone.0197868.g007
Discussion

This meta-analysis included 7 randomized studies that assessed the efficacy and safety of LMWH in more than 3,500 patients after knee arthroscopy. In clinical research, a RCT naturally represents the gold standard. [13] A previously published study indicated that in surgical practice, a RCT could answer at least 40% of the questions surrounding clinical decisions. [14] An article published in 1995 in The Lancet showed that 53% of clinical decisions were backed by a RCT in acute internal medicine. [15] Our meta-analysis showed that the symptomatic VTE rate was 0.5% (11/2,166) in the LMWH group versus 0.6% (10/1,713) in the control group. The risk of major VTE (symptomatic VTE, symptomatic DVT and symptomatic PE) was not decreased by LMWH prophylaxis. There was no efficacy for LMWH in patients undergoing knee arthroscopy in our research. This finding was in accordance with the result of a recent high quality RCT[9] and meta-analysis[16].

Proximal DVT was defined when the common femoral or popliteal vein was included [6]. Therefore, the other DVT of the lower extremity was the distal DVT. To date, the clinical relevance of distal VTE is strongly disputed, and treatment is currently not recommended[17–21]. These events were not a representation of clinically relevant VTE, and distal VTE does not require treatment particularly considering the bleeding risk[22]. The NNT (number needed to treat) undergoing knee arthroscopy was 1,000 (1/[0.6–0.5%]). If the symptomatic VTE events contained distal VTE events, the NNT was 143 (1/[24/1,713-15/2,166]). We determined that the difference between these two results was substantial. Thus, the patients with distal VTE determined the outcome of the meta-analysis. As previously discussed, we excluded the distal VTE events in the symptomatic VTE events in our research.

LMWH has been extensively employed for VTE prophylaxis when undergoing moderate and high-risk surgery[23]; however, the risk of bleeding with LMWH is higher than that with aspirin. [24–25] Therefore, the complications (e.g., major bleeding and minor bleeding) after LMWH treatment cannot be ignored. The safety of LMWH in arthroscopic surgery of the knee is also concerning. In this meta-analysis, we identified a nonsignificant increase in the risk of major bleeding in the LMWH group compared with the control group, which was inconsistent with Chapelle C et al.’s[8] findings in a non-major orthopaedic setting. The study showed that the major bleeding rate was 0.2% (4/2,166) in the LMWH group versus 0.1% (2/1,713) in the control group. Moreover, for major bleeding, the NNH (number needed to harm) undergoing knee arthroscopy was 1,000. Our meta-analysis indicated significantly less

![Fig 8. LMWH versus control. Minor bleeding during follow-up.](https://doi.org/10.1371/journal.pone.0197868.g008)
minor bleeding in the control group than in the LMWH group. As previously discussed, we attributed this bleeding to the pharmacological action of LMWH. There were no deaths reported in the randomized trials included in this meta-analysis. Clinically, in general, the risk of minor bleeding did not endanger the patient’s life. Therefore, we believe that it is relatively safe to use LMWH after arthroscopic surgery of the knee.

A survey study indicated that despite the lack of a solid evidence base, most patients receive thrombosis prophylaxis when undergoing knee arthroscopy.[26] Moreover, although the substantial majority of patients received VTE prophylaxis after orthopaedic surgery, a gap between the international guideline recommendations and clinical practice was identified. [27] Our meta-analysis also showed that LMWH prophylaxis does not reduce the risk of symptomatic VTE after knee arthroscopy.

**Limitations**

Several limitations cannot be neglected in this meta-analysis. First, the lack of RCTs was the most significant drawback, which increased the risk of bias in the study. Another main weakness of the lack of RCTs was the lack of correct stratification of the arthroscopic intervention. Second, heterogeneity between studies was common, such as with the asymptomatic DVT data in this meta-analysis. We performed sensitivity analyses to explain the source of heterogeneity. Third, the clinical situation of the patients and the patients’ intrinsic risk factors[28] were not included, which may have affected the studied outcomes. Fourth, the types and doses [29] of LMWH or use of different times for patients were not considered in this study. The physician experiences may have also affected the research outcomes. Therefore, more comprehensive and convincing RCTs are required to further evaluate the efficacy and safety of LMWH after knee arthroscopy.

**Conclusions**

This meta-analysis showed that there was no potential efficacy of LMWH in preventing symptomatic thrombosis after knee arthroscopy compared with a control group. Studies also indicated that there was no effect on the major bleeding rate compared with the control group. The potential adverse effects of LMWH, such as minor bleeding, should be considered. Thus, LMWH prophylaxis should not be routinely considered in patients undergoing arthroscopic surgery. However, the lack of RCTs and correct stratification in knee arthroscopy in our meta-analysis may have led to selection bias. Therefore, additional multi-centred prospective RCTs are necessary.

**Supporting information**

S1 Appendix. PRISMA checklist.
(DOC)

**Acknowledgments**

No other potential conflict of interests relevant to this paper were reported.

**Author Contributions**

**Data curation:** Jia-Liang Tian, Xian-Teng Yang, Li Sun.

**Formal analysis:** Ru-Yin Hu, Zhi-Hui Yan, Shan-Shan Li.

**Funding acquisition:** Xiao-Bin Tian.
Resources: Quan Xie.
Writing – original draft: Hai-Feng Huang.

References
1. van Adrichem RA, Nelissen RG, Schipper IB, Rosendaal FR, Cannegieter SC. Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study. J Thromb Haemost. 2015; 13(6):1441–8. https://doi.org/10.1111/jth.12996 PMID: 25940206.
2. Raskob GE, Angchaisuksi P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014; 12(10):1580–90. https://doi.org/10.1111/jth.12996 PMID: 25302663.
3. Roth VP. Prophylaxis of deep vein thrombosis in outpatients undergoing arthroscopic meniscectomy. Orthop Prax. 1995; 5:345–8.
4. Wirth T, Schneider B, Holtz D, Erni D, Zumstein MD, Ruffin GB, et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. Arthroscopy. 2001; 17(4):393–9. PMID: 11288011.
5. Michot M, Conen D, Stocker R, Stocker R, Luxi M, Trathnig S, et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low—molecular weight heparin. Arthroscopy. 2002; 18(3):257–63. PMID: 11877611.
6. Marlovits S, Striessnig G, Schuster R, Stocker R, Luxi M, Trathnig S, et al. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study. Arthroscopy. 2007; 23(7):696–702. https://doi.org/10.1016/j.arthro.2007.02.001 PMID: 17637403.
7. Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med. 2008; 149(2):73–82.PMID: 18626046.
8. Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S, et al. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. Arthroscopy. 2014; 30(8):987–96. https://doi.org/10.1016/j.arthro.2014.03.009 PMID: 24813323.
9. van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, et al. Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting. N Engl J Med. 2017; 376(6):515–25. https://doi.org/10.1056/NEJMoa1613303 PMID: 27959702.
10. Gray E, Mulloy B, Barrowcliffe TW. Heparin and Low-Molecular-Weight Heparin. Thromb Haemost. 2008; 99,807–18. https://doi.org/10.1160/TH08-01-0032 PMID: 18449410.
11. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995; 86(4):1368–73. PMID: 7632944.
12. Canata GL, Chiety A. Prevention of venous thromboembolism after ACL reconstruction: a prospective, randomized study. Knee Surgery and Orthopedic Sports. Medicine Congress 2003; Auckland, New Zealand; March 10–13.
13. Spindler KP, Kuhn JE, Dunn W, Matthews CE, Harrell FE Jr, Dittus RS. Reading and reviewing the orthopaedic literature: a systematic, evidence-based medicine approach. J Am Acad Orthop Surg. 2005; 13(4):220–9. PMID: 16112979.
14. Solomon MJ, McLeod RS. Should we be performing more randomized controlled trials evaluating surgical operations? Surgery. 1995; 118(3):459–67. PMID: 7652679.
15. Ellis J, Mulligan I, Rowe J, Sackett DL. Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine. Lancet. 1995; 346(8972):407–10. PMID: 7623571.
16. Ramos J, Perrotta C, Badariotti G, Berenstein G. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev. 2008; (4):CD005259. https://doi.org/10.1002/14651858.CD005259.pub3 PMID: 18843687.
17. Garry J, Duke A, Labropoulos N. Systematic review of the complications following isolated calf deep vein thrombosis. Br J Surg. 2016; 103(7):789–96. https://doi.org/10.1002/bjs.10152 PMID: 27060255.
18. Righini M, Galanau DP, Guenneguez H, Brisot D, Diard A, Faisse P, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol. 2016; 3(12):e556–e62. https://doi.org/10.1016/S2352-3026(16)30131-4 PMID: 27836513.
19. Palareti G, Cosmi B, Lessiani G, Rodorigo G, Guazzaloca G, Brusi C, et al. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost. 2010; 104(5):1063–70. https://doi.org/10.1160/TH10-06-0351 PMID: 20694281.

20. Galanaud JP, Sevestre MA, Genty C, Kahn SR, Pernod G, Rolland C, et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost. 2014; 12(4):436–43. https://doi.org/10.1111/jth.12512 PMID: 24450376.

21. Barco S, Corti M, Trinchero A, Picchi C, Ambaglio C, Konstantinides SV, et al. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. J Thromb Haemost. 2017; 15(7):1436–42. https://doi.org/10.1111/jth.13713 PMID: 28439954.

22. Chan NC, Stehouwer AC, Hirsh J, Ginsberg JS, Alazzoni A, Coppens M, et al. Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. Thromb Haemost. 2015; 114(5):1049–57. https://doi.org/10.1160/TH14-12-1006 PMID: 26134342.

23. Wellington K, McClellan K, Jarvis B. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. Drugs. 2001; 61(8):1185–209. PMID: 11465877.

24. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994; 308(6923):235–46. PMID: 8054013.

25. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention trial. Lancet. 2000; 355(9212):1295–302. PMID: 10776741.

26. van Adrichem RA, van Oosten JP, Cannegieter SC, Schipper IB, Nellissen RG. Thromboprophylaxis for lower leg cast immobilisation and knee arthroscopy: a survey study. Neth J Med. 2015; 73(1):23–9. PMID: 26219938.

27. Randelli F, Cimminiello C, Capozzi M, Bosco M, Cerulli G; Giotto Investigators. Real life thromboprophylaxis in orthopedic surgery in Italy. Results of the Giotto study. Thromb Res. 2016; 137:103–7. https://doi.org/10.1016/j.thromres.2015.11.007 PMID: 26581636.

28. Murphy RF, Heyworth B, Kramer D, Naqvi M, Miller PE, Yen YM, et al. Symptomatic Venous Thromboembolism After Adolescent Knee Arthroscopy. J Pediatr Orthop. 2016. https://doi.org/10.1097/BPO.0000000000000894 PMID: 27861210.

29. Fecher K, Ewald W, Fürst A, Hohmann V, Bramlage P. Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients. Unfallchirurg. 2013; 116(3):246–54. https://doi.org/10.1007/s00113-011-2094-7 PMID: 21909736.